Location Directory

Clinical trials in Birmingham, Alabama

This page shows live ClinicalTrials.gov search results for Birmingham, Alabama, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 10:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

9512

Shown on this page

Current sort

Institutions in Birmingham

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

University of Alabama at Birmingham

Live official records

Open in full search

Conditions: Diabetic Macular Edema
Interventions: Octreotide (drug), Placebo; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 90 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Desmoplastic Small Round Cell Tumor, Osteosarcoma, Recurrent Desmoplastic Small Round Cell Tumor, Recurrent Kidney Wilms Tumor, Recurrent Osteosarcoma, Refractory Desmoplastic Small Round Cell Tumor, Refractory Wilms Tumor, Wilms Tumor
Interventions: Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan, Trastuzumab Deruxtecan; Procedure · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 12 Years to 39 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 32
States / cities: Birmingham, Alabama • Los Angeles, California • Orange, California + 27 more

Conditions: Fallopian Tube Cancer, Peritoneal Neoplasms, Epithelial Ovarian Cancer
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 11
States / cities: Birmingham, Alabama • Los Angeles, California • Evanston, Illinois + 7 more

Conditions: Non-alcoholic Steatohepatitis
Interventions: Semaglutide, Placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 1,205 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 130
States / cities: Huntsville, Alabama • Chandler, Arizona • Peoria, Arizona + 100 more

Conditions: COPD
Interventions: EPIC (Empower People to Independence in COPD), Usual Care; Behavioral · Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Clostridoides Difficile Associated Disease
Interventions: C.difficile vaccine, Saline Placebo; Biological · Other
Lead sponsor: Pfizer; Industry
Eligibility: 65 Years and older
Enrollment: 32,500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2029
U.S. locations: 142
States / cities: Athens, Alabama • Guntersville, Alabama • Huntsville, Alabama + 90 more

Conditions: Emergencies
Interventions: Babies in the Owlet monitor group; Device
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 22 Weeks to 6 Months
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Non-segmental Vitiligo
Interventions: GIA632, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 24
States / cities: Birmingham, Alabama • Fountain Valley, California • San Diego, California + 21 more

Conditions: Heart Failure and Impaired Kidney Function
Interventions: balcinrenone/dapagliflozin 15 mg/10 mg and matching placebo for dapagliflozin 10 mg, balcinrenone/dapagliflozin 40 mg/10 mg and matching placebo for dapagliflozin 10 mg, dapagliflozin 10 mg and matching placebo for balcinrenone/dapagliflozin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 3,850 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 166
States / cities: Alexander City, Alabama • Birmingham, Alabama • Fairhope, Alabama + 142 more

Conditions: Intracranial Arteriosclerosis, Stroke
Interventions: Ticagrelor + Aspirin, Rivaroxaban + Aspirin, Clopidogrel + Aspirin, Risk Factor Management; Drug · Other
Lead sponsor: University of Florida; Other
Eligibility: 30 Years and older
Enrollment: 1,683 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 114
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 89 more

Conditions: Obesity or Overweight
Interventions: Placebo, Enicepatide; Combination Product
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 44
States / cities: Anniston, Alabama • Birmingham, Alabama • Tucson, Arizona + 37 more

Conditions: Non-small Cell Carcinoma, Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Carcinoma
Interventions: PF-08046054, Docetaxel monotherapy; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 680 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 241
States / cities: Alabaster, Alabama • Bessemer, Alabama • Birmingham, Alabama + 157 more

Clinical trials in Birmingham, Alabama

Filter and sort this location

Institutions in Birmingham

Live official records

Intranasal Delivery of Octreotide for Treatment of Diabetic Macular Edema

Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor

Predictors of Relapse of Ovarian, Peritoneal, and Fallopian Tube Cancers

Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)

Nurse Coach-Led Early Palliative Care for Older Adults With COPD and Their Care Partners: The Project EPIC Pilot RCT

A Study to Learn About a Clostridioides Difficile Vaccine in People 65 Years of Age and Older

Remote Oximeter Monitoring Post-discharge to Reduce Emergency Room Visits and Rehospitalization

A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo

Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function

Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)